February 1, 2012
By:Reflector
The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.
 |
January 1, 2012
By:Reflector
A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.
|
 | November 1, 2011
Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?
|
October 31, 2011
Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm.
|
October 1, 2011
Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence
|
 | September 1, 2011
Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
|
August 1, 2011
By:Reflector
HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
